{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-188577","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2022-07-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.949619+00:00","generated_at":"2026-06-24T20:44:51.111704+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX Phase 2 breast cancer study: Arm A meets ORR endpoint but Arm B fails; program paused, partnership sought","bullets":["Arm A in HR+/HER2- breast cancer met primary endpoint: ORR 15% (central review) in 47 patients unselected for CD166 expression.","Arm B (TNBC) did not pass futility boundary (ORR <10%); enrollment in Arms B and C discontinued.","Safety: 30% discontinued for AE; Grade 3+ ocular 15%, neuropathic 10%. Lower toxicity at 6 mg/kg dose.","Company will not further advance program alone due to financial market conditions; seeking a partnership.","CytomX intends to present full Phase 2 data at a medical conference in H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-188577","json":"https://secwatch.observer/filing/0001193125-22-188577.json","markdown":"https://secwatch.observer/filing/0001193125-22-188577.md","text":"https://secwatch.observer/filing/0001193125-22-188577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522188577/0001193125-22-188577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312522188577/d259130d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T20:44:51.111704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}